Ascletis Completes Enrollment in Phase III Trial of Denifanstat for Acne
核心洞察
Ascletis (搜索) Pharma has completed enrollment of 480 patients in a Phase III clinical trial for ASC40 (denifanstat), an oral tablet for moderate to severe acne (搜索).
The trial is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of once-daily ASC40 over 12 weeks.
Topline results from the Phase III trial are anticipated in the second quarter of 2025, potentially offering a novel acne (搜索) treatment option.
Ascletis (搜索) Pharma Inc. has announced the completion of enrollment for its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet being investigated for the treatment of moderate to severe acne (搜索). The trial, which enrolled a total of 480 patients, is a randomized, double-blind, placebo-controlled, multicenter study conducted in China.
The trial aims to evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne (搜索) vulgaris. Participants were randomized in a 1:1 ratio to receive either 50 mg of ASC40 or a matching placebo once daily for 12 weeks. The primary efficacy endpoints include the proportion of patients achieving treatment success at week 12, defined as at least a 2-point reduction in Investigator's Global Assessment (IGA) score from baseline and a score of clear (0) or almost clear (1). Additional endpoints are the percentage change from baseline in total lesion count and inflammatory lesion count at week 12.
ASC40: A Novel FASN Inhibitor
ASC40 (denifanstat) is a first-in-class, once-daily oral, selective small molecule inhibitor of fatty acid synthase (搜索) (FASN (搜索)). Its mechanism of action involves directly inhibiting facial sebum production through the inhibition of de novo lipogenesis (DNL) in human sebocytes, as well as reducing inflammation by decreasing cytokine secretion and Th17 differentiation. Ascletis (搜索) licensed ASC40 from Sagimet Biosciences Inc. for exclusive rights in Greater China.
Prior Phase II Results
Previously, Ascletis (搜索) reported positive results from a Phase II clinical trial of ASC40 for acne (搜索) vulgaris. The Phase II trial met its primary and key secondary endpoints, demonstrating superior efficacy compared to placebo. Specifically, 19.4% of patients achieved treatment success at week 12 with ASC40, compared to 5.1% in the placebo group. The drug also exhibited a good safety profile.
Management Commentary
"As a first-in-class once-daily oral drug candidate with novel mechanism for acne (搜索) treatment, ASC40 has shown positive efficacy and a good safety profile in the Phase II study. We look forward to announcing topline results of the ASC40 (denifanstat) Phase III trial in the second quarter 2025," said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis (搜索).
Topline results from the Phase III trial are expected in the second quarter of 2025.